SEC Filing Summary: Intrexon Corporation (Precigen, Inc.)
Business Context and Reporting Period
This Form 8-K was filed by Intrexon Corporation on November 12, 2019. The report concerns Precigen, Inc., a wholly owned subsidiary of Intrexon specializing in gene and cellular therapies. The filing serves as a Regulation FD disclosure to announce a conference call regarding Precigen's business and pipeline updates.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report announcing an event rather than a financial statement.
Material Changes
No material financial changes or operational metrics are detailed in this filing. The primary event is the scheduling of a business update conference call.
Guidance, Outlook, and Management Commentary
Management announced a conference call held on November 12, 2019, at 11:00 AM ET to provide updates on Precigen's business and pipeline. A slide presentation (Exhibit 99.1) was furnished to accompany the announcement. The filing explicitly states that the presentation and related information are not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Facts for Investor Verification
- Verify the content of the slide presentation (Exhibit 99.1) for specific pipeline and business updates.
- Confirm the status of Precigen as a wholly owned subsidiary of Intrexon Corporation.
- Note that this filing does not contain audited financial data or forward-looking financial guidance.
- Check Intrexon's investor website for the archived webcast of the November 12, 2019 call.